Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 6Thoracic 5Gastrointestinal 5Breast 3Gynecologic 2Sarcoma 1Myeloid 1

Conditions

Ovarian Neoplasms 508Uterine Cervical Neoplasms 361Endometrial Neoplasms 305Breast Neoplasms 130Colorectal Neoplasms 112Neoplasms 98Fallopian Tube Neoplasms 90Carcinoma, Non-Small-Cell Lung 87Stomach Neoplasms 83Pancreatic Neoplasms 79Lung Neoplasms 72Melanoma 68Prostatic Neoplasms 67Carcinoma, Ovarian Epithelial 65Neoplasm Metastasis 63Triple Negative Breast Neoplasms 51Vulvar Neoplasms 50Squamous Cell Carcinoma of Head and Neck 49Head and Neck Neoplasms 45Esophageal Neoplasms 43Uterine Neoplasms 40Peritoneal Neoplasms 40Urinary Bladder Neoplasms 38Carcinoma, Hepatocellular 35Carcinoma, Renal Cell 34Uterine Cervical Dysplasia 31Sarcoma 31Papillomavirus Infections 31Colonic Neoplasms 31Recurrence 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms, Second Primary × Gynecologic × Clear all
NCT06562647 2026-02-13

SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors

Cell Origin Biotech (Hangzhou) Co., Ltd.

Phase NA Recruiting
2 enrolled
Gynecologic

Ovarian Neoplasms, Neoplasms, Second Primary

NCT03458221 2023-04-18

STAPOVER

Gynaecologisch Oncologisch Centrum Zuid

Phase 2/3 Recruiting
148 enrolled
Gynecologic

Ovarian Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡